Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Expert Video Report on featured outcomes from novel NSCLC trials - AACR 2022

Reporting onsite from AACR 2022 in New Orleans, Nicolas Girard discusses practice changing results from the CheckMate 816 trial involving the addition of neoadjuvant nivolumab to chemotherapy for resectable (IB-IIIA) NSCLC. He further reviews the encouraging results at 2 years from CodeBreaK100 with sotorasib in pretreated patients with KRASp.G12C-mutated NSCLC.

Abstracts:
- CT012 - Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial - Nicolas Girard, et al.
- CT008 - Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100 - Grace K. Dy, et al.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.